EN DE
Watch Achieve Life Sciences, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Achieve Life Sciences, Inc (ACHV) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Achieve Life Sciences, Inc stock $3.39, price $6.40, that is 47.0% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AL Achieve Life Sciences, Inc logo Thin data Nov 10, 2026

Achieve Life Sciences, Inc

ACHV · US
Very expensive, weak quality

Our calculation puts a fair price 47% below what the stock costs today.

Moderate debt
Insiders sold $175,115 (6M)
Fair value $3.39 · Strongly overvalued
Quality 29/100
Weak Growth (revenue 5y −1.6 %/yr in USD)
Negative free cash flow
Trails peers (2/8)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Achieve Life Sciences, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$9.93 $1.98 Fair Value $3.39 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.98 – $9.93 · fair‑value band $2.55 – $4.24 · the $6.40 price screens above the $3.39 fair value. As of Nov 10, 2026.

Follow Achieve Life Sciences in your weekly email

Every Wednesday you see whether Achieve Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

Show moreShow less

The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol.

Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Stock analysis

Achieve Life Sciences, Inc (ACHV) currently trades at $6.40, while our estimate is $3.39, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.55 (bear) to $4.24 (bull), the price of $6.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Achieve Life Sciences, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$54.6M in FY2025.

Key figures

Market cap $741M Small · EPS (TTM) $−1.69 · Return on equity −845% · Return on assets (EBIT) −116% (5-year average) · Free cash flow −$49.5M · Net cash $6.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 142% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, ACHV screens richer than that median.

Fair Value

Bear $2.55 Fair Value $3.39 Bull $4.24
Price $6.40 · Downside -47.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 21
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 59
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 71
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $175,115 and none bought.

  • SaleRichard Alistair StewartDirector20,626 shares at $8.49$175,115Aug 19, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−72.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−44.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−405.5% (2011) → −418.6% (2016)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ACHV screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Achieve Life Sciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −47.0% · Bottom 25%
Profitability
Return on assets −130.8% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.52× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 34.45× · Priciest 25%
PEG 17.68× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ACHV
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ACHV
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ACHV
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ACHV
argenx SE ARGX $971.55 $908.40 −7% vs ACHV
CSL Limited CSL A$201.68 A$181.40 −10% vs ACHV
Moderna, Inc MRNA $250.83 $158.70 −37% vs ACHV
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ACHV
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ACHV
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ACHV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Achieve Life Sciences, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Achieve Life Sciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACHV

Frequently asked questions

Is Achieve Life Sciences, Inc (ACHV) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $3.39 versus a price of $6.40, about 47% lower (overvalued).
What is the fair value of ACHV?
Our estimate for Achieve Life Sciences, Inc is $3.39 (as of Nov 10, 2026), built from audited fundamentals. The current price: $6.40.
What is the quality score of ACHV?
Achieve Life Sciences, Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Achieve Life Sciences, Inc (ACHV)?
Our calculated price target is the estimate of $3.39 (as of Nov 10, 2026). Cautious scenario $2.55, optimistic scenario $4.24. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Achieve Life Sciences, Inc stock forecast for 2026?
Our estimate puts fair value at $3.39, about 47% lower versus a price of $6.40 (overvalued). Cautious scenario $2.55, optimistic scenario $4.24. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Achieve Life Sciences, Inc (ACHV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Achieve Life Sciences, Inc it is $3.39 per share (as of Nov 10, 2026), against a price of $6.40.
Is Achieve Life Sciences, Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ACHV trades above its calculated fair value: price $6.40, fair value $3.39, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACHV?
No. The price is what the market pays today ($6.40); the fair value is what the company's own numbers justify ($3.39). For Achieve Life Sciences, Inc the two are $3.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Achieve Life Sciences, Inc worth?
The market values Achieve Life Sciences, Inc at about $741M (market capitalisation, as of Nov 10, 2026). Per share that is $6.40; our models calculate a fair value of $3.39 per share.
What do the bullish and bearish scenarios say about ACHV?
Our models span a range for Achieve Life Sciences, Inc: cautious scenario $2.55, base $3.39, optimistic $4.24 per share (as of Nov 10, 2026, price $6.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ACHV?
The PEG ratio of Achieve Life Sciences, Inc is 17.68 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Achieve Life Sciences, Inc (ACHV)?
Balance-sheet figures for Achieve Life Sciences, Inc (as of Nov 10, 2026): debt of 0.52 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is ACHV from its 52-week high?
Achieve Life Sciences, Inc trades at $6.40, about 25% below its 52-week high of $8.53 and 142% above the low of $2.65 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.39 is for.
Which stocks are comparable to Achieve Life Sciences, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Achieve Life Sciences, Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $6.40, calculated fair value $3.39 (−47%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Achieve Life Sciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Achieve Life Sciences, Inc (ACHV)?
The closing price on Nov 10, 2026 was $6.40. Our estimate is $3.39, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Achieve Life Sciences, Inc right now?
The price sits above even our optimistic bull case ($4.24). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Achieve Life Sciences, Inc

How large is the market capitalisation of Achieve Life Sciences, Inc (ACHV)?
The market capitalisation of Achieve Life Sciences, Inc is $741M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Achieve Life Sciences, Inc (ACHV)?
Earnings per share at Achieve Life Sciences, Inc are $−1.69. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Achieve Life Sciences, Inc (ACHV)?
The return on equity (ROE) of Achieve Life Sciences, Inc is −845% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Achieve Life Sciences, Inc (ACHV)?
On an EBIT basis the return on assets of Achieve Life Sciences, Inc is −116% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Achieve Life Sciences, Inc (ACHV) generate?
The free cash flow of Achieve Life Sciences, Inc is −$49.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Achieve Life Sciences, Inc (ACHV) hold?
Achieve Life Sciences, Inc holds more cash than debt, $6.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Achieve Life Sciences, Inc in the live analysis

One click puts Achieve Life Sciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.